Sun Pharmaceutical Industries has reported its financial results for the second quarter of 2025, highlighting a strong performance characterized by significant revenue and profit growth. On October 28, 2025, the company announced a 9.01% increase in revenue year-over-year, alongside a remarkable 27.98% rise in profit. These results demonstrate the company’s robust recovery and operational efficiency in a challenging economic environment. In addition to year-over-year growth, Sun Pharmaceutical also showcased sequential growth, with revenues up 5.05% and profit rising by 7.21% compared to the previous quarter.
Sun Pharmaceutical 2025
The slight increase in Selling, General, and Administrative (SG&A) expenses reflects a controlled approach to operational costs, while operating income increased by 6.06% quarter-over-quarter and 23.42% year-over-year, indicating effective management of core operations. The company’s earnings per share (EPS) for Q2 reached ₹12.7, a 28.28% increase from the same quarter last year. With a market capitalization of ₹456,569.5 crore, Sun Pharmaceutical has seen strong investor confidence, reflected in its impressive year-to-date return of 51.09%. Analyst ratings are predominantly positive, with a strong consensus recommending “Buy,” suggesting favorable growth prospects.